Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 4/20 | 0.50 |
| ▸ | PPARA | Q07869 | 4/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22637884 | 0.89 | PTPN1 (0.52) | TDP1LMNATSHRPTPN1PPARD | |
| SCHEMBL7001607 | 0.84 | ALDH1A1 (0.57) | TDP1LMNATSHRPPARDPPARA | |
| SCHEMBL6631003 | 0.76 | PYGL (0.61) | TDP1LMNATSHRS1PR3S1PR4 | |
| SCHEMBL6630999 | 0.76 | PYGL (0.61) | TDP1LMNATSHRS1PR3S1PR4 | |
| SCHEMBL24660448 | 0.75 | ALDH1A1 (0.59) | LMNATSHRPTPN1TP53SMN1; SMN2 | |
| SCHEMBL18167908 | 0.75 | TACR1 (0.74) | LMNATSHRS1PR3TP53SMN1; SMN2 | |
| SCHEMBL20204206 | 0.75 | TACR1 (0.74) | LMNATSHRS1PR3TP53SMN1; SMN2 | |
| SCHEMBL6619964 | 0.75 | TDP1 (0.53) | TDP1LMNATSHRPPARDPPARA | |
| SCHEMBL15875270 | 0.75 | L3MBTL1 (0.50) | TDP1LMNATSHRPTPN1FFAR1 | |
| Trifluoroacetic Acid SCHEMBL6632834 | 0.74 | PTPN1 (0.49) | TDP1PTPN1PPARDPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789089-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2943487-B1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9220710-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2943487-A1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014110298-A1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | TDP1 1782/4885LMNA 3225/4885TSHR 4662/4885 |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | TDP1 1782/4885LMNA 3225/4885TSHR 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.